Archive for the ‘chart’ tag
Avandia – years of benefits
Unlike traditional therapies, Avandia targets the underlying causes of type 2 diabetes – insulin resistance and associated beta-cell failure giving your type 2 diabetes patients sustained glycemic control, and more to feel good about
Sustained glycemic control/Years of benefits.
Click here to see the details and full-size version in the gallery
This ad and thousands more can be seen on the AdPharm gallery, the largest online pharmaceutical advertising gallery.
Vyvanse web banner
Click here to see it on AdPharm
AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.
Vyvanse web banner
Click here to see it on AdPharm
AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.
Trelstar LA
Click on image to view ad details and full-size version on AdPharm
To see all of this brand’s ads on AdPharm, click here
Rituxan
Click on thumbnail to view the full-size ad on AdPharm
When planning a treatment course for DLBCL
Take the essential path toward improved survival
Rituxan + CHOP is proven to prolong survival in DLBCL
Brand name: Rituxan
Generic name/category: Rituximab, Monoclonal antibodies, Orphan drugs, Antineoplastic drugs
Company: Genentech BioOncology and Biogen idec
Country/Market: USA, North America
Indication(s)/use: diffuse large B cell lymphoma (DLBCL)
Target: Healthcare Professionals (HCP)
Tagline: Take the essential path toward improved survival
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – August 6, 2009
To see all of this brand’s ads on AdPharm, click here
Alexion – PNH threatening
PNH ??? progressive, life threatening…
and in your practice?
Patients in your practice may have PNH.
Visit us at PNHsource.com to learn more.
Paroxysmal nocturnal hemoglobinuria (PNH), sometimes referred to as Marchiafava-Micheli syndrome, is a rare, acquired, potentially life-threatening disease of the blood characterised by complement-induced hemolytic anemia (anemia due to destruction of red blood cells in the bloodstream), red urine (due to the appearance of hemoglobin in the urine) and thrombosis. PNH is the only hemolytic anemia caused by an acquired (rather than inherited) intrinsic defect in the cell membrane (deficiency of glycophosphatidylinositol leading to absence of protective proteins on the membrane). It may develop on its own (“primary PNH”) or in the context of other bone marrow disorders such as aplastic anemia (“secondary PNH”).
Brand name: PNH Source
Generic name/category: Disease awareness, web portal
Company: Alexion Pharmaceuticals
Country/Market: USA, North America
Indication(s)/use: Paroxysmal nocturnal hemoglobinuria (PNH)
Target: Healthcare Professionals (HCP)
Tagline: Innovators in complement inhibition
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Blood – September 17, 2009
To see all of this brand's ads on AdPharm, click here
0 views
Sep 17, 2009
Visit AdPharm.net for more pharmaceutical ads
Alexion – PNH vital organ
In PNH, their most vital organ is exploding.
What will you do?
Chronic hemolysis drives PNH morbidities and mortality.
Visit us at PNHsource.com to learn more.
Paroxysmal nocturnal hemoglobinuria (PNH), sometimes referred to as Marchiafava-Micheli syndrome, is a rare, acquired, potentially life-threatening disease of the blood characterised by complement-induced hemolytic anemia (anemia due to destruction of red blood cells in the bloodstream), red urine (due to the appearance of hemoglobin in the urine) and thrombosis. PNH is the only hemolytic anemia caused by an acquired (rather than inherited) intrinsic defect in the cell membrane (deficiency of glycophosphatidylinositol leading to absence of protective proteins on the membrane). It may develop on its own (“primary PNH”) or in the context of other bone marrow disorders such as aplastic anemia (“secondary PNH”).
Brand name: PNH Source
Generic name/category: Disease awareness, web portal
Company: Alexion Pharmaceuticals
Country/Market: USA, North America
Indication(s)/use: Paroxysmal nocturnal hemoglobinuria (PNH)
Target: Healthcare Professionals (HCP)
Tagline: Innovators in complement inhibition
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Blood – September 17, 2009
To see all of this brand's ads on AdPharm, click here
0 views
Sep 17, 2009
Visit AdPharm.net for more pharmaceutical ads
